Compare RDVT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | CTMX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.2M | 642.2M |
| IPO Year | 2017 | 2015 |
| Metric | RDVT | CTMX |
|---|---|---|
| Price | $69.28 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $62.00 | $12.10 |
| AVG Volume (30 Days) | 160.0K | ★ 5.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.00 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $90,252,000.00 | $76,201,000.00 |
| Revenue This Year | $16.31 | N/A |
| Revenue Next Year | $13.83 | $7.61 |
| P/E Ratio | $218.40 | ★ $22.58 |
| Revenue Growth | ★ 20.03 | N/A |
| 52 Week Low | $33.40 | $1.72 |
| 52 Week High | $67.68 | $8.21 |
| Indicator | RDVT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 82.15 | 62.72 |
| Support Level | $50.66 | $3.76 |
| Resistance Level | N/A | $3.90 |
| Average True Range (ATR) | 2.66 | 0.22 |
| MACD | 0.97 | 0.12 |
| Stochastic Oscillator | 96.04 | 90.34 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.